Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study.

Luigi GargiuloLuciano IbbaAndrea CorteseJessica AvaglianoMario ValentiAntonio CostanzoAlessandra Narcisi

Published in: Dermatology and therapy (2023)

We observed higher rates of EASI75/EASI90/EASI100 responses at week 16, compared with data from clinical trials. The safety profile of upadacitinib was favorable, as no AEs leading to discontinuation were experienced by our patients up to week 16.

Keyphrases

clinical trial
end stage renal disease
atopic dermatitis
ejection fraction
newly diagnosed
young adults
chronic kidney disease
physical activity
prognostic factors
peritoneal dialysis
placebo controlled
electronic health record
high intensity
big data
phase ii
drug induced
patient reported
phase iii